ATE169216T1 - Paclitaxel enthaltende injizierbare zusammensetzung - Google Patents

Paclitaxel enthaltende injizierbare zusammensetzung

Info

Publication number
ATE169216T1
ATE169216T1 AT94901593T AT94901593T ATE169216T1 AT E169216 T1 ATE169216 T1 AT E169216T1 AT 94901593 T AT94901593 T AT 94901593T AT 94901593 T AT94901593 T AT 94901593T AT E169216 T1 ATE169216 T1 AT E169216T1
Authority
AT
Austria
Prior art keywords
taxol
solution
composition containing
injectable composition
containing paclitaxel
Prior art date
Application number
AT94901593T
Other languages
English (en)
Inventor
David R Carver
Timothy R Prout
Hernita Ewald
Robyn Elliott
Paul Handreck
Original Assignee
Napro Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25644377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE169216(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napro Biotherapeutics Inc filed Critical Napro Biotherapeutics Inc
Application granted granted Critical
Publication of ATE169216T1 publication Critical patent/ATE169216T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
AT94901593T 1992-11-27 1993-11-18 Paclitaxel enthaltende injizierbare zusammensetzung ATE169216T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL607492 1992-11-27
US99550192A 1992-12-22 1992-12-22

Publications (1)

Publication Number Publication Date
ATE169216T1 true ATE169216T1 (de) 1998-08-15

Family

ID=25644377

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97121710T ATE274347T1 (de) 1992-11-27 1993-11-18 Stabile injizierbare paclitaxel lösung
AT94901593T ATE169216T1 (de) 1992-11-27 1993-11-18 Paclitaxel enthaltende injizierbare zusammensetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97121710T ATE274347T1 (de) 1992-11-27 1993-11-18 Stabile injizierbare paclitaxel lösung

Country Status (12)

Country Link
US (7) US5733888A (de)
EP (4) EP0835657B1 (de)
JP (1) JP2880292B2 (de)
AT (2) ATE274347T1 (de)
AU (1) AU5612694A (de)
CA (2) CA2308082A1 (de)
DE (2) DE69320206T2 (de)
DK (2) DK0835657T3 (de)
ES (2) ES2119996T3 (de)
GR (1) GR3027724T3 (de)
PT (1) PT835657E (de)
WO (2) WO1994012031A1 (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0835657T3 (da) * 1992-11-27 2005-01-10 Mayne Pharma Usa Inc Stabil, injicerbar paclitaxelsammensætning
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
FR2710534B1 (fr) * 1994-09-28 1996-07-05 Bristol Myers Squibb Co Solvant de stabilisation, composition pharmaceutique le contenant, et son procédé de préparation.
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
DE19536165A1 (de) * 1995-09-28 1997-04-03 Basf Ag Verfahren zur Reinigung von alkoxylierten Fetten
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN1209059A (zh) * 1995-12-21 1999-02-24 基因实验室技术有限公司 紫杉烷类组合物及方法
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
NZ336381A (en) 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
WO2000023070A1 (en) 1998-10-20 2000-04-27 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
KR20060110013A (ko) 1999-05-14 2006-10-23 니리어스 파마슈티컬즈, 인크. 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들, 상기조절인자들의 합성 및 상기 조절인자들의 사용 방법
DE19925211B4 (de) * 1999-06-01 2006-01-12 PBS Pharmaceutical Bulk Substances SA Kit zur Herstellung einer Formulierung von Paclitaxel
WO2001052838A1 (en) * 2000-01-20 2001-07-26 Baker Norton Pharmaceuticals, Inc. Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof
MXPA01009900A (es) * 2000-02-02 2003-08-20 Univ Florida State Res Found Formulaciones de taxano que tienen solubilidad mejorada.
JP2003523769A (ja) 2000-02-23 2003-08-12 ヴァーテックス ファーマシューティカルズ （サンディエゴ）エルエルシー 改変された蛍光タンパク質
EP1310248A4 (de) 2000-08-10 2008-05-21 Takeda Pharmaceutical Pharmazeutische zusammenstellung
JP4922507B2 (ja) * 2000-08-10 2012-04-25 武田薬品工業株式会社 医薬組成物
WO2002047610A2 (en) * 2000-11-16 2002-06-20 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product dicovery
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US7141251B2 (en) 2001-04-06 2006-11-28 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
JP2005515187A (ja) * 2001-11-26 2005-05-26 スーパージェン インコーポレイテッド ポリオキシエチル化ひまし油を使用する医薬組成物の調製方法
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
CA2470826A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
JP4975964B2 (ja) * 2002-06-26 2012-07-11 メディゲーネ アクチエンゲゼルシャフト 脂肪親和性化合物から成る陽イオン性リポソームの製法
KR101184374B1 (ko) * 2002-08-02 2012-09-20 니리어스 파마슈티컬즈, 인코퍼레이션 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성 방법
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7112581B2 (en) * 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
EP1558241A2 (de) * 2002-11-08 2005-08-03 Bristol-Myers Squibb Company Pharmazeutische zusammensetzungen und verfahren zur verwendung von taxan-derivaten
KR20050100397A (ko) * 2003-02-11 2005-10-18 노오쓰웨스턴 유니버시티 나노결정질 표면 코팅을 위한 방법 및 물질, 및 이의상부로의 펩티드 양친매성 나노섬유의 부착
JP2007523862A (ja) * 2003-06-20 2007-08-23 ネレアス ファーマシューティカルズ インコーポレイテッド 癌、炎症及び感染性疾患の治療のための、［３．２．０］複素環式化合物およびそれらの類縁体の使用
ZA200600473B (en) * 2003-06-20 2007-04-25 Univ California Salinosporamides and methods for use thereof
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
DK1694660T3 (da) * 2003-12-12 2009-08-10 Biorganica Ltda Fremgangsmåde til fremstilling af vandfri og hydrerede aktive farmaceutiske bestanddele (API's); stabile farmaceutiske sammensætninger fremstillet af disse og anvendelser af disse sammensætninger
EP1711486B1 (de) * 2004-01-23 2011-05-11 Nereus Pharmaceuticals, Inc. Als antimikrobielle mittel geeignete bisindolpyrrole
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
EP2025679A3 (de) * 2004-04-30 2009-07-08 Nereus Pharmaceuticals, Inc. [3,2,0]-Heterocyclische Verbindungen und Verfahren zu Ihrer Verwendung
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
WO2006060676A1 (en) * 2004-12-03 2006-06-08 Dana Farber Cancer Institute Compositions and methods for treating neoplastic diseases
KR20060121721A (ko) * 2005-05-23 2006-11-29 주식회사 중외제약 테트라플루오로벤질 유도체 또는 그의 염을 함유하는주사제용 조성물
CA2611592A1 (en) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
US7893299B2 (en) 2005-07-21 2011-02-22 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-αmodulators; syntheses of such modulators and methods of using such modulators
BRPI0615292A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
DK3311805T3 (da) * 2005-08-31 2020-04-14 Abraxis Bioscience Llc Sammensætninger, der omfatter svært vandopløselige farmaceutiske midler og antimikrobielle midler
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
FR2912745A1 (fr) * 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
BRPI0912234A2 (pt) * 2008-05-12 2015-10-06 Nereus Pharmaceuticals Inc derivados de salinosporamida como inibidores de proteassomas
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8128951B2 (en) * 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
CN102970990A (zh) 2010-05-03 2013-03-13 帝国制药美国公司 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
US20140018398A1 (en) 2011-03-29 2014-01-16 Sanofi Otamixaban formulations with improved stability
WO2013006972A1 (en) * 2011-07-11 2013-01-17 Mercure Claude Novel anti-cancer isocarbostyril alkaloid conjugates
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2777691A1 (de) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Reinigung der flüssigen Hilfsstoffen
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
AU2015312134A1 (en) 2014-09-02 2017-03-23 Bhupinder Singh Deuterated or a non-deuterated molecule and pharmaceutical formulations
WO2016044649A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Injectable formulations for treating cancer
WO2016057563A1 (en) 2014-10-08 2016-04-14 Pacific Northwest Diabetes Research Institute Methods and compositions for increasing the potency of antifungal agents
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
BR112017018954A2 (pt) 2015-03-06 2018-05-15 Beyondspring Pharmaceuticals, Inc. uso de forma mutante de proteína ras e método para tratar câncer
CN108026075B (zh) 2015-07-13 2021-06-29 大连万春布林医药有限公司 普那布林组合物
US10561766B2 (en) 2015-09-15 2020-02-18 W. L. Gore & Associates, Inc. Drug composition and coating
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
IL268305B1 (en) 2017-02-01 2024-04-01 Beyondspring Pharmaceuticals Inc Palinabolin in combination with one or more G-CSF drugs for use in the drug treatment of docetaxel-induced neutropenia
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
EP3773612A4 (de) 2018-03-28 2022-01-12 Herbalife International of America, Inc. Acetylierung von polysacchariden
CA3112201A1 (en) * 2018-10-16 2020-04-23 US Nano Food & Drug INC Intratumor injection formulation
IL297015A (en) 2020-04-13 2022-12-01 US Nano Food & Drug INC Basic formulation of intratumoral chemotherapy injection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS552421B2 (de) * 1971-08-06 1980-01-19
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
ATE129006T1 (de) * 1990-02-15 1995-10-15 Pq Corp Verfahren zur behandlung von bratöl unter verwendung einer aluminiumoxid- und amorphen kieselerdezusammensetzung.
TW223634B (de) * 1991-03-18 1994-05-11 Kingston David G I
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
DK0835657T3 (da) * 1992-11-27 2005-01-10 Mayne Pharma Usa Inc Stabil, injicerbar paclitaxelsammensætning
KR100371062B1 (ko) * 1992-11-27 2003-04-21 에프.에이치.포울딩 앤드 컴퍼니 리미티드 안정성이향상된주사가능한택솔조성물및이를제형화하는방법
US5281727A (en) * 1992-11-27 1994-01-25 Napro Biotherapeutics, Inc. Method of using ion exchange media to increase taxane yields
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5733388A (en) 1994-08-11 1998-03-31 Daido Tokiushuko Kabushiki Kaisha Steel composition for bearings and method of producing the same

Also Published As

Publication number Publication date
EP1384474A1 (de) 2004-01-28
US20040204479A1 (en) 2004-10-14
US6140359A (en) 2000-10-31
US6306894B1 (en) 2001-10-23
US6770670B2 (en) 2004-08-03
US20030065022A1 (en) 2003-04-03
ES2119996T3 (es) 1998-10-16
US5733888A (en) 1998-03-31
JP2880292B2 (ja) 1999-04-05
DK0835657T3 (da) 2005-01-10
EP0674510B1 (de) 1998-08-05
EP1500393A1 (de) 2005-01-26
EP0674510A4 (de) 1995-08-12
CA2149150C (en) 2000-08-01
DE69333605D1 (de) 2004-09-30
WO1994012030A1 (en) 1994-06-09
ES2224200T3 (es) 2005-03-01
AU5612694A (en) 1994-06-22
CA2308082A1 (en) 1994-06-09
CA2149150A1 (en) 1994-06-09
PT835657E (pt) 2004-11-30
DE69320206T2 (de) 1999-02-11
DE69333605T2 (de) 2005-02-03
EP0835657A1 (de) 1998-04-15
EP0674510A1 (de) 1995-10-04
US5972992A (en) 1999-10-26
WO1994012031A1 (en) 1994-06-09
ATE274347T1 (de) 2004-09-15
JPH08503945A (ja) 1996-04-30
GR3027724T3 (en) 1998-11-30
US5977164A (en) 1999-11-02
DE69320206D1 (de) 1998-09-10
EP0835657B1 (de) 2004-08-25
DK0674510T3 (da) 1999-05-10

Similar Documents

Publication Publication Date Title
ATE169216T1 (de) Paclitaxel enthaltende injizierbare zusammensetzung
ATE201328T1 (de) Hochkonzentriertes immunglobulin-präparat und verfahren zu seiner herstellung
DK47189D0 (da) Bredspektret konserveringsmiddel med synergistisk biocidvirkning
NO307205B1 (no) Preparater basert på virkestoffer fra taxanklassen samt perfusjonspreparater inneholdende disse
ATE141498T1 (de) Sonnenschutzmittel
DE3682208D1 (de) Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
DE69307977T2 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
ATE82139T1 (de) Eine lipidloesliche substanz enthaltende waessrige fluessigkeit.
PT91602A (pt) Processo para a preparacao de compostos espiro com accao antibacteriana e de composicoes farmaceuticas que os contem
FI964285A0 (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
ATE225340T1 (de) Einschlusskomplexe von taxol oder taxotere oder taxus-extrakten und cyclodextrinen, ihre herstellung und ihre verwendung
HUT66153A (en) Pharmaceutical compositions which can be used for preventing and treating of chemotherapy-induced alopecia
ATE52691T1 (de) Pharmazeutische zubereitung.
PL289266A1 (en) Method of stabilizing 3-isothiazolones and compositions containing them
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
KR940008695A (ko) 안티트롬빈 iii제제
ATE122352T1 (de) 3-(3-ethyl-1,2,4-oxadiazol-5-yl)-1- azabicycloheptan, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zubereitungen.
TH1086A (th) ส่วนประกอบสารทำให้ผ้านุ่ม
KR890001568A (ko) 돼지 이질의 예방 및 치료제
KR860003012A (ko) (-)시스-1,2-에폭시프로필포스폰산과 아미노산과의 염을 함유하는 수용성 제약 조성물

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked